The Trump administration rolled out an executive order this month designed to speed psychedelic treatments for serious mental illness, but legal experts say the directive will likely matter more as a political statement than as actual policy change.
The order directs federal agencies to collaborate on expanding access to psychedelic medications, including joint efforts between the Department of Veterans Affairs to share data and boost clinical trial enrollment. It also promises faster rescheduling should any psychedelic drug win FDA approval.
But Mason Marks, a law professor at Florida State University and psychedelic research fellow at Harvard Law School, sees the real value elsewhere. While the concrete legal provisions will have "some minimal impact," Marks said the order's symbolic force could matter significantly. The administration paired the announcement with a high-profile press conference featuring podcaster Joe Rogan and retired Navy Seal Marcus Luttrell, an unusual move for a president openly championing psychedelic research.
"It's quite unusual for a president to be promoting psychedelic research in such a public way," Marks said. During the event, Rogan claimed a personal conversation with the president sparked the order.
Cat Packer, director of drug markets and legal regulation at the Drug Policy Alliance, sees the order as a window into shifting Republican politics. Support for psychedelics now spans elected officials, veteran advocates, and high-profile figures with White House access. "It's a welcome sign that the federal government is taking psychedelic research seriously," Packer said, though she flagged a potential cost.
The administration's focus on medicalized treatment for veterans could narrow who actually benefits from legal changes, Packer warned. "Without sustained investments in healthcare access, community-based treatment and housing, we cannot truly address America's mental health crisis," she said, noting the Trump administration has cut funding to such programs.
The psychedelics order arrives in the shadow of a prior executive directive on cannabis. Trump ordered the reclassification of marijuana from Schedule I to Schedule III in December. Yet even with that earlier push, plus Biden-era momentum, the Justice Department only this week announced it would actually move on the promise. Acting Attorney General Todd Blanche said the DOJ is ordering an expedited hearing to fully reschedule marijuana.
That glacial pace reveals institutional resistance inside federal law enforcement. Packer noted the Drug Enforcement Administration has historically fought marijuana rescheduling. "There's already been some evidence of institutional resistance," she said, adding that Trump himself has suggested parts of his administration are dragging their feet on cannabis.
The psychedelics order may face fewer obstacles. Unlike the cannabis directive, which hinged on a single rescheduling action, this one contains multiple straightforward directives, such as funding state-level research. More importantly, the FDA is already open to psychedelics, with several drugs potentially weeks to years away from approval. Psilocybin for treatment-resistant depression is already far along in trials.
That proximity to approval, however, makes some of the order's provisions redundant. The order directs the DEA to reschedule any drug completing Phase 3 trials, but federal law already requires that within 90 days. "You can't get much faster than that," Marks said.
One provision does worry Marks. The order suggests the FDA's safety review should be accelerated, potentially using artificial intelligence to speed the process. Marks fears that could create blind spots. Psychedelic trials have already drawn scrutiny for failing to report adverse events properly. If reviewers miss something under AI-assisted acceleration, a drug could hit the market with dangerous side effects, leading to a costly recall that would damage the entire field.
Packer echoed the caution. "Faster review and expanded research can be positive, but only if paired with rigorous evidence, strong patient protections and a broader public-health approach. These substances hold promise, but they are not a panacea," she said.
Author James Rodriguez: "The order is a genuine political shift on psychedelics, but translating symbolic momentum into actual faster approvals without cutting corners on safety will test whether this administration can follow through."
Comments